Skip to main content
    E

    Envoy Medical Inc. (COCH)

    Official site

    HEALTHCARE • MEDICAL DEVICES • NASDAQ

    $6.92
    +0.18 (+2.75%)

    Market Cap: $52.16M

    Last updated: Nov 17, 2026 at 10:59 AM ET

    Envoy Medical Inc. (COCH) Financials: Revenue, Profit and Cash Flow

    Updated Nov 5, 2026. Financial statements from company filings, amounts in US dollars.

    Envoy Medical reported revenue of $241.00K for the fiscal year ended Dec 31, 2025, up 7.1% from the year before. That year, net income was -$23.76M with a net margin of -9857.3%, operating cash flow was -$18.20M and free cash flow was -$18.38M. The quarter ended Sep 30, 2026 had revenue of $66.00K and net income of -$3.93M.

    Revenue and Margins

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$241.00K+7.1%-262.7%-9240.7%-9857.3%
    Dec 2024$225.00K-28.8%-229.8%-8558.2%-9242.2%
    Dec 2023$316.00K+33.3%-149.7%-5809.8%-9469.0%
    Dec 2022$237.00KN/A-110.1%-3673.4%-6718.6%
    Dec 2021$0N/AN/AN/AN/A
    Dec 2020N/AN/AN/AN/AN/A
    Annual, fiscal years ended Dec 2020 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, the net loss widened from the year before. In the quarter ended Sep 2026, the net loss narrowed from the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020
    Revenue$241.00K$225.00K$316.00K$237.00K$0N/A
    Cost of revenue$874.00K$742.00K$789.00K$498.00K$0N/A
    Gross profit-$633.00K-$517.00K-$473.00K-$261.00K$0N/A
    Research and development$12.49M$10.18M$8.96M$4.97M$0$0
    Operating income-$22.27M-$19.26M-$18.36M-$8.71M-$5.20M-$701
    Net income-$23.76M-$20.80M-$29.92M-$15.92M-$251.63K-$701
    EBITDA-$19.31M-$17.94MN/AN/A$210.40K-$701
    Fiscal years ended Dec 2020 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Revenue$66.00K$51.00K$39.00K$75.00K$42.00K$78.00K$46.00K$42.00K$56.00K$68.00K$59.00K$95.00K
    Gross profit-$178.00K-$227.00K-$274.00K-$136.00K-$161.00K-$156.00K-$180.00K-$115.00K-$131.00K-$177.00K-$94.00K-$168.00K
    Operating income-$5.54M-$5.57M-$5.96M-$6.38M-$5.26M-$5.07M-$5.11M-$4.55M-$4.97M-$4.85M-$4.88M-$6.72M
    Net income-$3.93M-$5.98M-$4.35M-$6.59M-$6.48M-$5.69M-$5.00M-$4.62M-$5.96M-$3.95M-$6.27M-$4.99M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, cash and equivalents exceeded short-term debt of $174.00K by $3.56M. Shareholder equity was negative, at -$12.16M, as total liabilities of $20.32M exceeded total assets of $8.56M.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020
    Total assets$8.56M$11.54M$8.27M$2.56M$426.90M$119.99K
    Current assets$6.28M$8.90M$7.46M$1.65M$863.17K$25.00K
    Cash and equivalents$3.74M$5.48M$4.22M$183.00K$149.84K$25.00K
    Total liabilities$20.32M$30.38M$10.05M$38.75M$38.62M$95.69K
    Short-term debt$174.00K$143.00K$158.00K$448.00K$460.00KN/A
    Long-term debtN/A$18.72M$0$33.40M$23.48MN/A
    Shareholder equity-$12.16M-$18.84M-$1.78M-$36.20M-$36.71M$24.30K
    Fiscal years ended Dec 2020 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total assets$19.16M$23.95M$29.82M$8.56M$8.18M$9.90M$10.38M$11.54M$9.40M$6.74M$8.48M$8.27M
    Total liabilities$20.30M$20.25M$19.27M$20.32M$15.71M$39.76M$34.61M$30.38M$27.93M$19.12M$15.89M$10.05M
    Cash and equivalents$14.57M$19.68M$25.25M$3.74M$3.56M$5.29M$5.31M$5.48M$4.42M$1.75M$4.95M$4.22M
    Shareholder equity-$1.53M$3.30M$10.16M-$11.77M-$7.66M-$29.86M-$24.22M-$18.84M-$18.53M-$12.39M-$7.41M-$1.78M
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended Dec 2025.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
    Operating cash flow-$18.20M-$17.95M-$17.09M-$8.80M-$3.24M
    Capital expenditures$179.00K$980.00K$153.00K$218.00K$125.00K
    Free cash flow-$18.38M-$18.93M-$17.24M-$9.02M-$3.37M
    Dividends paid$1.82M$2.45M$0N/AN/A
    Share repurchases$62.00K$0N/AN/A$9.13M
    Investing cash flow-$179.00K-$980.00K-$153.00K-$218.00K-$425.00M
    Financing cash flow$16.63M$20.20M$21.28M$8.09M$428.37M
    Fiscal years ended Dec 2021 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Operating cash flow-$5.03M-$5.46M-$6.06M-$5.68M-$4.33M-$4.46M-$3.73M-$5.09M-$2.62M-$4.65M-$5.59M-$11.14M
    Capital expenditures$27.00K$6.00K$0$172.00K$0$1.00K$6.00K$534.00K$615.00K$790.00K$109.00K$21.00K
    Free cash flow-$5.06M-$5.46M-$6.06M-$5.86M-$4.33M-$4.46M-$3.73M-$5.63M-$3.24M-$5.44M-$5.70M-$11.17M
    Last 12 quarters

    Frequently Asked Questions About COCH

    What is Envoy Medical's annual revenue?

    Envoy Medical reported revenue of $241.00K for the fiscal year ended Dec 31, 2025.

    How fast is Envoy Medical's revenue growing?

    Revenue was up 7.1% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was 0.6%.

    Is Envoy Medical profitable?

    No. Envoy Medical reported net income of -$23.76M for the fiscal year ended Dec 31, 2025, with a net margin of -9857.3%.

    How much free cash flow does COCH generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of -$18.20M minus capital expenditures of $179.00K produced free cash flow of -$18.38M.

    How much debt does Envoy Medical have?

    The balance sheet dated Dec 31, 2025 reported short-term debt of $174.00K and cash and equivalents of $3.74M.